Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics is pursuing precision medicine with a well diversified and competitively priced pipeline in various stages of development. Along with strong partnerships, regulatory clarity and financial stability, the company puts a strong emphasis on the patient's quality of life and drug tolerability. With consistent symptom score improvement and potential for lower dosing, it has the potential to differentiate itself from other drugs in the space, making it a good investment choice for the future.

Bears say

Relay Therapeutics is currently overvalued and its stock is at risk of significant decline. The company's technology may have potential in precision medicine, but it is still early stage and risky. With only one drug candidate in phase 1 trials, it may take a considerable amount of time and resources for Relay Therapeutics to bring a product to market and generate revenue. Additionally, the company's high reliance on its proprietary Dynamo platform and recent equity offering raise concerns about its financial stability and long-term prospects.

RLAY has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 11 analysts, RLAY has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.